Cardiol Therapeutics Inc. (CRDL) completed a private placement of 11,423,078 units at $1.30 each, generating $14.85 million in gross proceeds after the underwriter exercised the full over‑allotment option. Each unit consists of one Class A common share and a half warrant that can be exercised at $1.75 within 24 months, providing investors with a modest upside potential while the company secures immediate liquidity.
The financing follows a $13.5 million private placement announced on January 16 2026 and a $11.4 million raise in October 2025, underscoring the company’s ongoing need for capital to fund its cash‑burn intensive pipeline. The new capital extends Cardiol’s runway into the third quarter of 2026, giving the company additional time to complete the Phase III MAVERIC trial for CardiolRx and to pursue other development milestones without the pressure of an imminent funding gap.
Proceeds will be allocated across several key areas: a substantial portion will support the MAVERIC Phase III trial, which is critical for advancing CardiolRx toward regulatory approval; a smaller allocation will cover general and administrative expenses; and the remainder will be used to maintain working capital and support day‑to‑day operations. This targeted use of funds aligns with the company’s strategy to prioritize clinical milestones while maintaining operational stability.
While the issuance of new shares and warrants does dilute existing shareholders, the dilution is offset by the liquidity gained, which is essential for a clinical‑stage company that relies on external financing to sustain its development program. The company’s current ratio of 3.89 indicates solid short‑term liquidity, but the negative EBITDA of $26.17 million in the last twelve months highlights the need for continued capital injections.
Cardiol’s lead candidate, CardiolRx, has received U.S. FDA orphan drug designation for recurrent pericarditis, positioning the company favorably in a niche market with limited competition. The private placement reinforces investor confidence in the company’s pipeline, but the repeated capital raises also signal that the company remains heavily cash‑burn dependent and will likely pursue additional financing in the near term to support its ambitious development agenda.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.